Addition of N‐terminal pro‐B  natriuretic peptide to soluble fms‐like tyrosine kinase‐1/placental growth factor ratio &gt; 38 improves prediction of pre‐eclampsia requiring delivery within 1 week: a longitudinal cohort study

Sabrià, Enric; Lequerica-Fernández, Paloma; Lafuente-Ganuza, Paula; Eguia-Ángeles, E.; Escudero, Ana I; Martínez‐Morillo, Eduardo; Barceló, Carme Pigem; Álvarez, Francisco V.

doi:10.1002/uog.19040

Cited by 22 publications

(15 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, although PIERS and PREP are of value in established cases of PE, considerable clinical resources are expended monitoring women considered to be at high risk of PE. This issue contains several publications demonstrating the added clinical value of repeat soluble fms‐like tyrosine kinase‐1 (sFlt‐1):PlGF ratio testing and use of additional (N‐terminal pro‐B natriuretic peptide (NT‐proBNP) and C‐terminal pro‐endothelin‐1 (CT‐pro‐ET1)) biomarkers in the high‐risk population. Whilst these are encouraging clinical findings, it is important to bear in mind that, as for early‐pregnancy PE screening tests, combining biochemical and biophysical markers may allow for even better prediction of adverse pregnancy outcome.…”

Section: Prognostic Markers In Pre‐eclampsiamentioning

confidence: 99%

Pre‐eclampsia and the cardiovascular–placental axis

Thilaganathan

2018

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Section: Prognostic Markers In Pre‐eclampsiamentioning

confidence: 99%

Pre‐eclampsia and the cardiovascular–placental axis

Thilaganathan

2018

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

“…Sugulle et al 6 measured MR-proANP at 24 to 42 weeks' gestation in 77 normotensive and 107 PE pregnancies and found that MR-proANP had an AUC of 0.85 in discriminating between PE pregnancies and normotensive pregnant controls, which was inferior to that of sFlt-1 (AUC, 0.94). In contrast to copeptin and MR-proANP, another cardiovascular biomarker, N-terminal pro-B natriuretic peptide (NT-proBNP), has shown incremental value in predicting short-term delivery due to PE 19 when added to sFlt-1/PlGF ratio > 38. Similarly, a recent study demonstrated that adding NT-proBNP > 174 pg/mL to an sFlt-1/PlGF ratio > 45 increases significantly the positive predictive value of sFlt-1/PlGF ratio 20 .…”

Section: Discussionmentioning

confidence: 99%

Copeptin and mid‐regional pro‐atrial natriuretic peptide in women with suspected or confirmed pre‐eclampsia: comparison with sFlt‐1/PlGF ratio

Neuman

Meer

Saleh

et al. 2020

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Objectives Arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) may contribute to the pathogenesis of pre‐eclampsia (PE), but their role remains to be elucidated. Our aims were to evaluate the surrogates of AVP and ANP, C‐terminal pro‐AVP (copeptin) and mid‐regional pro‐ANP (MR‐proANP), as biomarkers for the prediction of PE‐related pregnancy complications and whether they are associated with angiogenic markers and/or clinical manifestations of PE. Methods This was a retrospective analysis of a prospective cohort study that enrolled pregnant women with suspected or confirmed PE, between December 2013 and April 2016. From each patient, a blood sample was obtained at study entry and serum levels of copeptin, MR‐proANP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured. We evaluated the ability of sFlt‐1, PlGF, sFlt‐1/PlGF ratio, copeptin and MR‐proANP, assessed either alone or combined with traditional predictors (gestational age, parity, diastolic blood pressure and proteinuria), to predict maternal complications and fetal/neonatal complications. Models were compared using concordance statistic (C‐index). Results A total of 526 women were evaluated in the study. Women with confirmed PE displayed elevated serum copeptin and MR‐proANP levels in comparison to those with suspected PE but no hypertensive disease of pregnancy. When combined with traditional predictors, the sFlt‐1/PlGF ratio displayed a higher C‐index than copeptin and MR‐proANP (0.76, 0.63 and 0.67, respectively, vs 0.60 for the traditional predictors alone) for the prediction of maternal complications. Similarly, for the prediction of fetal/neonatal complications, the sFlt‐1/PlGF ratio displayed a higher C‐index than copeptin and MR‐proANP when added to the traditional model (0.83, 0.79 and 0.80, respectively, vs 0.79 for the traditional predictors alone). When subdividing women according to sFlt‐1/PlGF ratio (≥ 85 vs < 85), no differences in copeptin levels were observed, while MR‐proANP level was elevated in women with sFlt‐1/PlGF ratio ≥ 85. Multiple regression analysis revealed that copeptin and MR‐proANP were independent determinants of proteinuria. Conclusions Copeptin and MR‐proANP have limited value in predicting PE‐related complications when compared with the sFlt‐1/PlGF ratio. However, both copeptin and MR‐proANP were associated with proteinuria, with copeptin exerting this effect independently of the sFlt‐1/PlGF ratio. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.

show abstract

“…Recent research [25][26][27] has described the added value of repeat testing of soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio, alone or with N-terminal pro B-type natriuretic peptide or C-terminal proendothelin-1 biomarkers, in the follow-up of pre-eclampsia. Both sFlt-1 and PlGF are produced by the placenta.…”

Section: Evidence Of Maternal Cardiovascular Maladaptation and Pre-ecmentioning

confidence: 99%

Role of placenta in development of pre‐eclampsia: revisited

Verlohren

2020

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Addition of N‐terminal pro‐B natriuretic peptide to soluble fms‐like tyrosine kinase‐1/placental growth factor ratio > 38 improves prediction of pre‐eclampsia requiring delivery within 1 week: a longitudinal cohort study

Cited by 22 publications

References 61 publications

Pre‐eclampsia and the cardiovascular–placental axis

Pre‐eclampsia and the cardiovascular–placental axis

Copeptin and mid‐regional pro‐atrial natriuretic peptide in women with suspected or confirmed pre‐eclampsia: comparison with sFlt‐1/PlGF ratio

Role of placenta in development of pre‐eclampsia: revisited

Contact Info

Product

Resources

About